Rare Disease ReportADA-SCID (aka Bubble Baby Disease) Cured by Gene TherapyRare Disease ReportA study published in in the Journal of Clinical Investigation revealed that gene therapy cured 9 of 10 children with adenosine deaminase-deficient severe comb… Continue reading
Nature.com |
CRISPR studies muddy results of older gene research
Nature.com Jason Sheltzer, a cancer biologist at Cold Spring Harbor Laboratory in New York, was on the hunt for genes involved in tumour growth. He and his colleagues planned to disable genes using the popular gene-editing tool CRISPR–Cas9, then look for changes … |
R & D Magazine |
Investigational Immunotherapy Boosts Response With Pembrolizumab in Advanced Melanoma
R & D Magazine The investigational immunotherapy indoximod appeared to enhance response rates when given with FDA-approved immunotherapy pembrolizumab (Keytruda) in patients with advanced melanoma, according to interim results from a phase I/II clinical trial. Adding the IDO-pathway inhibitor indoximod to pembrolizumab improved the melanoma response rateMedical Xpress ‘Excited’: Reaction to Advanced Melanoma ComboMedscape |
Engadget |
AI predicts the layout of human stem cells
Engadget The structures of stem cells can vary wildly, even if they’re genetically identical — and that could be critical to predicting the onset of diseases like cancer. But how do you know what a stem cell will look like until it’s already formed? That’s … Machine learning predicts the look of stem cellsNature.com Get a colorful 3-D view of human stem cells online with the Allen Cell ExplorerGeekWire GLOBAL STEM CELL MARKET FORECAST 2017-2025PR Newswire (press release) The San Diego Union-Tribune –Yahoo Finance –Bioscience Technology all 50 news articles » |
Clinical Oncology News |
CAR T-Cell Study in NHL Patients Shows Activity and Feasibility
Clinical Oncology News San Diego—Once again, a study has found that chimeric antigen receptor (CAR) T cells have impressive activity in highly treatment-experienced patients with a refractory hematologic malignancy. In this Phase II trial, the focus was non-Hodgkin lymphoma … |